Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01204307
What this trial is testing

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Who this might be right for
Advanced Non-Squamous Non-Small Cell Lung Cancer
Chang Gung Memorial Hospital 101
Testing effectiveness (Phase 2)UnknownNCT04808752
What this trial is testing

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Who this might be right for
Lung Cancer
Zhejiang Cancer Hospital 63
Early research (Phase 1)Study completedNCT07271446
What this trial is testing

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Precision Biotech Taiwan Corp. 8
Testing effectiveness (Phase 2)Study completedNCT03414814
What this trial is testing

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Who this might be right for
Locally Advanced or Metastatic NSCLC
Seoul National University Hospital 15
Large-scale testing (Phase 3)Study completedNCT01719536
What this trial is testing

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Who this might be right for
NSCLC
Betta Pharmaceuticals Co., Ltd. 296
Large-scale testing (Phase 3)Looking for participantsNCT04951635
What this trial is testing

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 150
Not applicableStudy completedNCT00997230
What this trial is testing

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m

Who this might be right for
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca 4,243
Post-approval studies (Phase 4)Not Yet RecruitingNCT07469488
What this trial is testing

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors+1 more
Shanghai Pulmonary Hospital, Shanghai, China 122
Testing effectiveness (Phase 2)UnknownNCT03654027
What this trial is testing

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Who this might be right for
Non-small Cell Lung Cancer
First Affiliated Hospital of Guangxi Medical University 84
Testing effectiveness (Phase 2)Looking for participantsNCT07362940
What this trial is testing

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Who this might be right for
Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd. 110
Testing effectiveness (Phase 2)UnknownNCT04063462
What this trial is testing

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Large-scale testing (Phase 3)Study completedNCT02454933
What this trial is testing

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Who this might be right for
Locally Advanced or Metastatic EGFR T790M+ NSCLC
AstraZeneca 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Not applicableAvailableNCT07601399
What this trial is testing

An EAP Treatment Protocol of Zipalertinib

Who this might be right for
Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Not applicableStudy completedNCT02321046
What this trial is testing

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 26
Testing effectiveness (Phase 2)Study completedNCT03513666
What this trial is testing

Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 40
Not applicableLooking for participantsNCT07230691
What this trial is testing

Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 380
Post-approval studies (Phase 4)Study completedNCT01203917
What this trial is testing

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
AstraZeneca 1,060
Testing effectiveness (Phase 2)Active Not RecruitingNCT06391944
What this trial is testing

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Who this might be right for
Local Advanced or Metastatic NSCLCHarboring EGFR Common Mutation
Shanghai JMT-Bio Inc. 161
Next Page